ANBT
SUPN icon

American National Bank & Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

American National Bank & Trust’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6
Closed -$165 – 677
2023
Q3 		$165 Sell
6
-170
-97% -$5.17K ﹤0.01% 584
2023
Q2 		$5.29K Hold
176
– – ﹤0.01% 445
2023
Q1 		$6.38K Hold
176
– – ﹤0.01% 429
2022
Q4 		$6K Buy
+176
New +$6.12K ﹤0.01% 423

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American National Bank & Trust's SUPN Position: Q4 2023 in Review

American National Bank & Trust sold out of Supernus Pharmaceuticals (SUPN) in Q4 2023, closing a stake of 6 shares — an estimated $165 sold.

American National Bank & Trust first reported a position in SUPN in Q4 2022 and held it in 4 quarters. The position peaked at $6.38K in Q1 2023. 246 funds tracked by Wall St. Rank hold SUPN as of Q4 2023.

  • American National Bank & Trust reported no remaining Supernus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • American National Bank & Trust sold 6 Supernus Pharmaceuticals shares in Q4 2023, an estimated $165.
  • American National Bank & Trust first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • American National Bank & Trust's Supernus Pharmaceuticals position peaked at $6.38K in Q1 2023.
  • 246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2023.

Based on American National Bank & Trust's 13F filing for Q4 2023, filed 8 Feb 2024.